GNF-2

BeschreibungGNF-2 is an allosteric inhibitor of Bcr-Abl (IC50 = 267 nM). It is selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 μM. It inhibits proliferation of Ba/F3 cells (IC50 = 138 nM). GNF-2 (10 μM) reduces viral titers in Vero cells infected with infectious bronchitis virus (IBV), a coronavirus, via inhibition of IBV surface glycoprotein-induced syncytia formation and virus-cell fusion. It inhibits LPS-induced production of nitric oxide (NO) and TNF-α in BV-2 microglia when used at concentrations of 10 and 20 μM. GNF-2 (1 and 10 mg/kg) reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain induced by complete Freund’s adjuvant (CFA). It also decreases mechanical and thermal hyperalgesia in a mouse model of diabetic neuropathy induced by streptozotocin (STZ; ).

VerwendenBcr-abl Inhibitor is an inhibitor of c-Abl and Bcr-abl activity. It is a COVID19-related research product.